### **ADVANCED TRACK**

### **DIABETES AND OTHER HEALTH CONDITIONS**



Alexandra Reiher MD Centura – St. Anthony's Hospital, Lakewood CO



#EPICconf2021

www.EPICconferences.org





### **CONFLICTS OF INTEREST: NONE**



#EPICconf2021

www.EPICconferences.org



## **DIABETES AND OTHER HEALTH CONDITIONS**

### TOPICS:

- Musculoskeletal
- Neurologic/Memory
- Osteoporosis
- Dermatologic Conditions





## **MUSCULOSKELETAL CONDITIONS:**

### Hand/Wrist:

Carpal Tunnel Syndrome (10-20%)

Dupytren's Contracture (15-45%)

**Trigger Finger** 

Shoulder:

Adhesive capsulitis (Frozen Shoulder) (10-30%)

Rotator cuff tendonopathy

calcified periarthritis

Limited Joint Mobility Syndrome

**Diabetic Amyotrophy** 

**Diabetic Myonecrosis** 

**Stiff Person Syndrome** 



Image borrowed from www.mayoclinic.org

![](_page_4_Picture_16.jpeg)

#EPICconf2021

www.EPICconferences.org

![](_page_4_Picture_19.jpeg)

## LIMITED JOINT MOBILITY (CHEIROPATHY)

Associated with poor glycemic control, advanced age, and smoking

Increased risk with duration of diabetes

Affects upper limbs and hands

Thick, rigid, waxy skin

At risk for other microvascular complications

Clinical findings: Prayer Sign, Table Top Sign

Treatment: smoking cessation, improve glycemic control, physical therapy, NSAIDs

![](_page_5_Picture_8.jpeg)

![](_page_5_Picture_9.jpeg)

# **DIABETIC MYONECROSIS**

- Spontaneous infarction of muscle, rare disease associated with long-standing diabetes (type 1 and type 2)
- Increased mortality rate due to associated cardiovascular disease
- Present with acute pain and swelling in an extremity
- No prior history of trauma to the affected region
- Markers of inflammation are elevated
- Diagnosed by ultrasound or MRI
- Treatment symptomatic management, generally self-limiting
  - bedrest, glycemic control, NSAIDs
- Resolves after 6-12 weeks
- Anti-platelet therapy (aspirin) usually prescribed
- Recurrence rate near 50%

![](_page_6_Picture_13.jpeg)

# #EPICconf2021

www.EPICconferences.org

![](_page_6_Picture_16.jpeg)

![](_page_6_Figure_17.jpeg)

MPOWERING

# DIABETIC AMYOTROPHY

Diabetic lumbosacral plexopathy

- Often in well-controlled or recently diagnosed type 2 diabetes (1% of patients with T2D)
- Presentation: acute onset proximal leg pain, muscle weakness, loss of muscle mass
- Starts in one leg, often progresses to involve both legs
- Associated with significant weight loss in 80% of patients
- Pathophysiology: ischemic neural injury due to microvasculitis
- Self-limited course, most will have some clinical improvement (though rarely 100%)
  - foot drop, neuropathic pain can persist for years
- Muscular weakness or pain can persist
- Treatment: pain relief, supportive management
- Limited data to support use of steroids or immunosuppressive therapy

![](_page_7_Figure_13.jpeg)

## **NEUROLOGIC CONDITIONS/MEMORY**

Increased risk of cognitive decline in both T1D and T2D

T2D: Associated with impaired attention, processing and motor speed,

executive functioning, and verbal memory

![](_page_8_Figure_5.jpeg)

### Younger age at onset of T2D significantly associated with a higher risk of subsequent dementia

Longer duration of diabetes associated with faster cognitive decline

- Regarding the metabolic syndrome and cognitive decline: hyperglycemia has the strongest association with risk of developing cognitive impairment
- Diabetes is considered a risk factor for both vascular dementia and Alzheimer's disease (AD)
- Obesity is also a risk factor for development of dementia

Mechanism not entirely understood

one theory - insulin receptor dysfunction in the brain (including the hippocampus), although not related to circulating insulin levels

increased expression of pro-inflammatory cytokines in the brain in DM - role in neuronal damage

### **NEUROLOGIC CONDITIONS/MEMORY**

In the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions Complications (EDIC) Studies:

T1D with higher A1c (>8.8%): moderate declines in motor speed and psychomotor efficiency compared to patients with better glycemic control (A1c <7.4%)

children diagnosed with T1D: greater cognitive impairment present in children diagnosed before age 7 compared to those diagnosed at a later age

# **NEUROLOGIC CONDITIONS/MEMORY**

**Prevention?** 

Small studies have shown improvement in executive function in T2D after 6 months of aerobic intervention, another study showed improvement in verbal memory after exercise and dietary intervention for 6 months

Intensive glycemic control in T2D associated with a slowed rate of brain atrophy on MRI

Medications: GLP1 agonists

Liraglutide (Victoza) was associated with reduced memory impairment and increased synaptic plasticity in animal models

Liraglutide and Lixisenatide: both reversed memory impairment, prevented deterioration of synaptic plasticity in the hippocampus, reduced beta-amyloid plaque in the cortex in animal studies

Supplements: anti-oxidants and anti-inflammatory medications

curcumin, vitamin E - improved learning and memory in animal studies

![](_page_10_Picture_9.jpeg)

### **OSTEOPOROSIS**

Increased risk in T1D, appears to be an increased risk in T2D (but less clear)

Increased risk observed after at least 10 years' history of DM Unclear if glycemic control decreases risk or not

Can be related to increased risk of falling (if vision loss, neuropathy) Peripheral neuropathy associated with increased bone loss and fracture risk at foot and ankle

Diabetic medications can play a role

![](_page_11_Picture_5.jpeg)

# DIABETIC MEDICATIONS AND RISK OF OSTEOPOROSIS/FRACTURES

Medications	Bone Mineral Density	Risk of Fracture
Metformin	=/ 🕇	<b>↓</b> /=
Sulfonlyureas (ie glipizide)	no data	↓ /=/ 🕇
TZD (ie actos/pioglitazone)	<b> </b>  =	1 /=
GLP1 agonists ( <u>ie</u> Trulicity, Ozempic, Victoza, <u>Rybelsus</u> )	1=	=
DPP4 inhibitors ( <u>ie</u> Januvia, <u>Tradjenta,</u> Nesina)		<b>↓</b> /=
SGLT2 inhibitors ( <b>Invokana</b> , limited data for Steglatro, Farxiga, Jardiance)	=	=/ 1
Insulin	=	1

![](_page_12_Picture_2.jpeg)

#EPICconf2021

www.EPICconferences.org

Adapted from Ferrari et al. 2018

![](_page_12_Picture_6.jpeg)

## **DERMATOLOGIC CONDITIONS**

- Acanthosis nigricans
- Bullous Diabeticorum
- Diabetic Dermopathy
- Sclerodermiform disorders
- Grannuloma Annulare
- Necrobiosis Lipoidica Diabeticorum
- Diabetic foot ulcerations

![](_page_14_Picture_0.jpeg)

### **ACANTHOSIS NIGRICANS**

Skin thickening in fold, particularly armpits velvety appearance
Due to hyperinsulinemia
Seen in type 2 diabetes
Can also be associated with skin tags
Associated with the metabolic syndrome in obesity
Typical areas affected: armpits, neck, umbilicus, elbows
Treatment: reducing insulin resistance weight loss, exercise, metformin

![](_page_14_Picture_3.jpeg)

![](_page_14_Picture_4.jpeg)

![](_page_15_Picture_0.jpeg)

# **GRANULOMA ANNULARE (GA)**

Benign, self-limiting

Dermatitis of the pretibial regions, extensor surfaces of the limbs

Seen in response to infections, malignancy

Can by seen in patients with diabetes

Women affected more than men

Affected areas - those exposed to trauma

back of hands and feet, fingers, elbows, arms, legs

Asymptomatic

- Occasionally itchy/burning sensation
- Possibly due to release of lymphokines, stimulating synthesis and activity of collagenase

Can disappear spontaneously within 2 years

![](_page_15_Picture_13.jpeg)

### **NECROBIOSIS LIPODICA DIABETICORUM (NLD)**

Unknown origin 0.3-1.6% of patients with diabetes/year 80% women, Caucasian Can occur at any age, most often 4<sup>th</sup>-6<sup>th</sup> decades Development is not associated with glycemic control Degenerative disease of collagen in the dermis and subcutaneous fat with an atrophic epidermis Typically present on both legs, pretibial region 15% of cases involve other areas - abdomen, upper limbs, scalp Can be asymptomatic, or associated with burning/itching If ulcerations develop, can be painful Spontaneous resolution 10-20% cases Treatment avoid trauma to the area drug treatment - limited effectiveness intralesional injection, oral use of corticosteroids topical agents if lesion are flat

![](_page_16_Picture_2.jpeg)

### REFERENCES

- Signla R, Gupta Y, and Kalra S. Musculoskeletal effects of diabetes mellitus. Recent advances in Endocrinology. 2015;65(9):1024-1027.
- Horton WB et al. Diabetic muscle infarction: a systematic review. BMJ Open Diabetes Research and Care 2015;3e000082.
- Zilliox LA et al. Diabetes and Cognitive Impairment. Curr Diab Rep 2016;16(9):87.
- Amidei CB et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. JAMA 2021;324(16)1640-1649.
- Ferrari et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporosis International 2018; 29:2585-2596
- Mendes AL, Haddad V, and Miot HA. Diabetes mellitus and the skin. An Bras Dermatol. 2017;92(1):8-20.